Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 18F-AraG Clear all

Conditions: Graft Versus Host Disease
Interventions: [18F]F-Ara-G; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: PASC Post Acute Sequelae of COVID-19
Interventions: A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only), B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only); Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Sacramento, California • San Francisco, California

Conditions: Advanced Non Small Cell Lung Cancer
Interventions: [18F]F-AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Non-small Cell Lung Cancer
Interventions: [18F]F-ARAG PET; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cancer
Interventions: [18F]F-AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lung Cancer, Nonsmall Cell
Interventions: [18F]F-AraG Imaging; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Non-small Cell Lung Cancer
Interventions: 18F-AraG; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 21 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit
Interventions: [18F]F-AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Stanford, California • Portland, Oregon

Conditions: HIV Infections
Interventions: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine); Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cancer
Interventions: [18F]F-AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Covid19, SARS-CoV Infection
Interventions: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine); Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bladder Cancer
Interventions: Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: Lawrence Fong; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Melanoma
Interventions: Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT; Drug · Biological · Other
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: [18F]F-AraG Injection; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Cancer, Clear Cell Renal Cell Carcinoma
Interventions: 177Lu girentuximab, Nivolumab, Cabozantinib, ArabinoFuranosylGuanine [18F]F-AraG; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-368, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: La Jolla, California • Sacramento, California • Stanford, California + 7 more

Conditions: Non Small Cell Lung Cancer
Interventions: [18F]F AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Palo Alto, California • Sacramento, California • Stony Brook, New York

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions: [18F]-AraG radiotracer, Chemotherapy, Radiotherapy; Drug · Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Non-Hodgkin's Lymphoma
Interventions: [ 18F]F-AraG PET; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Esophageal Cancer
Interventions: ArabinoFuranosylGuanine [18F]F-AraG; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Detection of Graft Versus Host Disease With [18F]F-AraG

Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

Test-retest Evaluation of [18F]F-AraG PET

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans

[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients

Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

Imaging Immune Activation in HIV by PET-MR

[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy

Imaging Immune Activation in COVID-19

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

[18F]-AraG PET Imaging in LA HNSCC

18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)